CureVac N.V. (CVAC)
NASDAQ: CVAC · Real-Time Price · USD
5.12
0.00 (0.00%)
Dec 5, 2025, 4:00 PM EST - Market closed
CureVac Revenue
CureVac had revenue of 54.13M EUR in the quarter ending September 30, 2025, a decrease of -89.04%. This brings the company's revenue in the last twelve months to 70.74M, down -86.98% year-over-year. In the year 2024, CureVac had annual revenue of 535.18M with 895.54% growth.
Revenue (ttm)
70.74M EUR
Revenue Growth
-86.98%
P/S Ratio
9.91
Revenue / Employee
71,964 EUR
Employees
983
Market Cap
1.15B USD
Revenue Chart
* This company reports financials in EUR.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
CVAC News
- 3 days ago - BioNTech Achieves Minimum Condition in CureVac Exchange Offer - GlobeNewsWire
- 8 days ago - CureVac N.V. (CVAC) Shareholder/Analyst Call Prepared Remarks Transcript - Seeking Alpha
- 10 days ago - CureVac Announces Voting Results of Extraordinary General Meeting - Accesswire
- 12 days ago - CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2025 and Provides Business Updates - Accesswire
- 2 months ago - CureVac: The Hidden Value Of The mRNA Wallet - Seeking Alpha
- 4 months ago - CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business Updates - Accesswire
- 4 months ago - CureVac settles patent dispute litigation with Pfizer and BioNTech - Reuters
- 5 months ago - CureVac Announces Voting Results of General Meeting - Accesswire